Drugs for Neglected Diseases initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Drugs for Neglected Diseases initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH142021D
  • |
  • Pages: 32
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Drugs for Neglected Diseases initiative (DNDi) is a non-profit drug research and development (R&D) organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis (HAT, or sleeping sickness), leishmaniasis, and Chagas disease, and conducts research and development projects for other neglected diseases including malaria, paediatric HIV, mycetoma, hepatitis C, and filarial infections. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. It also offers research programs for various organizations. It collaborates with private biotechnology companies, public institutions, academia and NGOs. The organization operates in Switzerland, the US, Kenya, India, Brazil, Malaysia and Japan. DNDi is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Takeda Pharma Enters into Agreement with DNDi 11

Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12

Optibrium Enters into Partnership with Imperial College London and DNDi 13

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14

Institut Pasteur Korea Enters into Research Agreement with DNDi 15

DNDi Enters into Agreement with Takeda Pharma 16

Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17

Celgene Global Health Expands Research Agreement DNDi 18

Institut Pasteur Korea and DNDi Enter into Research Agreement 19

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21

Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23

Drugs for Neglected Diseases initiative - Key Employees 24

Drugs for Neglected Diseases initiative - Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Strategy And Business Planning 27

Nov 08, 2017: DNDi/GARDP opens new South Africa liaison office, hosted by South African Medical Research Council 27

Corporate Communications 28

Aug 08, 2017: DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years 28

Government and Public Interest 29

Apr 13, 2018: Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa 29

Feb 06, 2018: New open source drug discovery project aims to develop mycetoma treatment 30

Other Significant Developments 31

Jan 18, 2018: Epichem Awarded One Year Contract Extension from DNDi 31

Appendix 32

Methodology 32

About GlobalData 32

Contact Us 32

Disclaimer 32

List of Figures

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Key Facts 2

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Drugs for Neglected Diseases initiative, Deals By Therapy Area, 2012 to YTD 2018 8

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Takeda Pharma Enters into Agreement with DNDi 11

Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12

Optibrium Enters into Partnership with Imperial College London and DNDi 13

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14

Institut Pasteur Korea Enters into Research Agreement with DNDi 15

DNDi Enters into Agreement with Takeda Pharma 16

Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17

Celgene Global Health Expands Research Agreement DNDi 18

Institut Pasteur Korea and DNDi Enter into Research Agreement 19

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21

Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23

Drugs for Neglected Diseases initiative, Key Employees 24

Drugs for Neglected Diseases initiative, Other Locations 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Drugs for Neglected Diseases initiative, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com